UniQure, Aehr Test Systems surge premarket; Snap, Leidos fall

Investing.com - U.S. stock futures were broadly steady on Wednesday as investors geared up for a key Federal Reserve interest rate decision and monitored reports on the details of a preliminary Middle East peace agreement.

By 08:40 ET (012:40 GMT), the Dow futures contract fell 0.1%, S&P 500 futures had edged up 0.1%, and Nasdaq 100 futures had gained 0.5%.

Healthcare and technology stocks were among the notable movers in premarket trading, while investors also reacted to fresh analyst actions and merger developments.

Here are some of the biggest premarket U.S. stock movers today:

• Snap shares remained under pressure after tumbling 9.6% in the previous session following the unveiling of its standalone augmented reality glasses, dubbed "SPECS." Investors appeared skeptical about the commercial prospects of the company’s latest hardware push.


• UniQure shares surged 67.5% after the gene therapy developer said the U.S. Food and Drug Administration had agreed that three-year data from its Phase I/II study of AMT-130 could serve as the primary basis for a Biologics License Application seeking accelerated approval for Huntington’s disease.


• Aehr Test Systems jumped 11% after the semiconductor test equipment maker announced a follow-on production order for a fully automated FOX-XP wafer-level burn-in system from a major silicon photonics customer. The system is expected to be delivered within the next six months.


• Genco Shipping & Trading rose 8% after Diana Shipping increased its acquisition proposal to $27.34 per share, consisting of cash and stock. Diana said the revised offer represents a substantial premium to Genco’s share price prior to its initial proposal.


• T1 Energy gained 1.9% after Bernstein SocGen Group initiated coverage of the solar and battery storage company with a Market Perform rating and a $9 price target, citing both growth opportunities and ongoing legal risks.


• Leidos Holdings slipped 1.3% after BofA Securities downgraded the defense and information technology contractor to Neutral from Buy and cut its price target to $125 from $200.

You May Also Be Interested In

• Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal
• Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Sector Deal
• Virginia approves American Water and Essential Utilities merger